Skip to main content

Moderna, Inc. Rest of world revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

Rest of world revenue at Moderna, Inc. came to $692.0M for the fiscal year to 31 Dec 2025, down 18.9% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 20 Feb 2026.

By fiscal year

$0Dec 2019$6.0MDec 2020$5.4BDec 2021$7.3BDec 2022$3.6BDec 2023$853.0MDec 2024$692.0MDec 2025
Moderna, Inc. Rest of world revenue, every reported period
Period endingRest of world revenueChange on a yearFiled
31 Dec 2025$692.0Mdown 18.9%20 Feb 2026
31 Dec 2024$853.0Mdown 76.3%21 Feb 2025
31 Dec 2023$3.6Bdown 50.7%23 Feb 2024
31 Dec 2022$7.3Bup 34.0%24 Feb 2023
31 Dec 2021$5.4B—25 Feb 2022
31 Dec 2020$6.0M—26 Feb 2021
31 Dec 2019$0—27 Feb 2020

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: COVID revenue · Stand-ready manufacturing revenue · RSV revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · United States revenue · Europe revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.